Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2AYS0
|
|||
| Drug Name |
PF-06473871
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Hypertrophic scars [ICD-11: EE60; ICD-10: L73.0] | Phase 2 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CCN2 messenger RNA (CCN2 mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02205476) A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study. U.S. National Institutes of Health. | |||
| REF 2 | A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast Reconstr Surg Glob Open. 2018 Sep 6;6(9):e1861. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.